Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allarity TherapeuticsALLR +3.36%26 Debt-to-Equity is 3.11 as of Mar. 2026, which is 4343% above its 10-year median of 0.07. GuruFocus rates ALLR with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 965 Biotechnology companies, Allarity Therapeutics ranks worse than 96.27% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Allarity Therapeutics's Debt-to-Equity or its related term are showing as below:
ALLR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -11.2 Med: 0.07 Max: 3.11
Current: 3.11
During the past 7 years, the highest Debt-to-Equity Ratio of Allarity Therapeutics was 3.11. The lowest was -11.20. And the median was 0.07.
ALLR's Debt-to-Equity is ranked worse than 96.27% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs ALLR: 3.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Allarity Therapeutics Debt-to-Equity Related Terms
Allarity Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Allarity Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALLR vs TVGN, LGVN, PLUR: Debt-to-Equity Comparison
For the Biotechnology subindustry, Allarity Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allarity Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Allarity Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allarity Therapeutics (ALLR) has a Debt-to-Equity of 3.11 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Allarity Therapeutics and its competitors. This is 4343% above median its historical median of 0.07. According to the industry distribution chart, Allarity Therapeutics ranks #929 out of 965 companies in the Biotechnology industry, placing it in the top 96.3%.
Is Allarity Therapeutics' Debt-to-Equity too high?
Allarity Therapeutics' current Debt-to-Equity of 3.11 is 4343% above median its 10-year median of 0.07. The Biotechnology industry median Debt-to-Equity is 0.16. Allarity Therapeutics' value of 3.11 is 1843.8% above this industry median. Based on the distribution chart, Allarity Therapeutics ranks #929 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' Debt-to-Equity compare to TVGN and LGVN?
According to the Biotechnology industry distribution chart, Allarity Therapeutics ranks #929 out of 965 companies for Debt-to-Equity. This places Allarity Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Allarity Therapeutics' value of 3.11 is 1843.8% above this benchmark. While the company's 10-year median is 0.07 vs. the industry median of 0.16, Allarity Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allarity Therapeutics's current Debt-to-Equity of 3.11 is 1843.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Allarity Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allarity Therapeutics's current Debt-to-Equity is 3.11, which is 4343% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current Debt-to-Equity of 3.11. The current Debt-to-Equity is 3.11, which is 4343% above median its 10-year median of 0.07 and 1843.8% above the Biotechnology industry median of 0.16. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current Debt-to-Equity is 3.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score
Get the complete analysis for ALLR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALLR has been successfully added to your 
